drugset / Trial / NCT07298343
Evaluating the Efficacy and Tolerability of ZED1227 in Subjects With Non-responsive Celiac Disease
Phase 2
Recruiting
356 enrolled
Dr. Falk Pharma GmbH
Takeda Development Center Americas, Inc. · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
A study to discover if ZED1227 can improve continued celiac disease symptoms despite a gluten-free diet
Timeline
- Start
- 2024-06-10
- Primary completion
- 2027-08
- Completion
- 2027-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ZED1227 | Small molecule | — | Oral |